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Abstract  20 
Background: Achromobacter spp. are recognized as an emerging pathogen in 21 
patients with Cystic Fibrosis (CF). Though recent works have established species-22 
level identification using nrdA sequencing, there is a dearth in knowledge relating to 23 
species-level antimicrobial susceptibility patterns and antimicrobial combinations 24 
which hampers the use of optimal antimicrobial combinations for the treatment of 25 
chronic infections. The aims of this study were i) to identify at species-level referred 26 
Achromobacter isolates ii) to describe species-level antimicrobial susceptibility 27 
profiles iii) to determine the most promising antimicrobial combination for chronic 28 
Achromobacter infections. 29 
Methods: A total of 112 multidrug-resistant (MDR) Achromobacter spp. isolates from 30 
39 patients were identified using nrdA sequencing. Antimicrobial susceptibility and 31 
combination testing were carried out using the Etest method.  32 
Results: We detected six species of Achromobacter and found that A. xylosoxidans 33 
was the most prevalent species. Interestingly, sequence analysis showed it was 34 
responsible for persistent infection (18/28 patients) followed by A. ruhlandii (2/3 35 
patients). Piperacillin-tazobactam (70.27%) and cotrimoxazole (69.72%) were the 36 
most active antimicrobials. Differences were observed in species-level susceptibility 37 
to ceftazidime, carbapenems, ticarcillin-clavulanate, and tetracycline. Antimicrobial 38 
combinations with cotrimoxazole or tobramycin demonstrate the best synergy while 39 
cotrimoxazole gave the best susceptibility breakpoint Index values. 40 
Conclusions: This study enriches the understanding of MDR Achromobacter spp. 41 
epidemiology, confirms prevalence and chronic colonization of A. xylosoxidans in CF 42 
 
 
lungs. It presents in vitro data to support the efficacy of new combinations for use in 43 
the treatment of chronic Achromobacter infections.  44 
Keywords: Achromobacter spp.; A. xylosoxidans; Cystic Fibrosis; Antimicrobial 45 
susceptibility testing; Synergy testing; Etest 46 
 
 
1.0 Introduction  47 
Several pathogens have been reported as causing chronic infections but 48 
Achromobacter spp. have increasingly been implicated as causal agents of infection 49 
and colonisation in CF individuals (1-7). National CF registries have reported slight 50 
increasing rates of Achromobacter spp. colonisation/infection in individuals (8) 51 
varying between 2 and 17 % (9). 52 
Achromobacter spp. are aerobic, Gram-negative, catalase- and oxidase-positive, 53 
non-fermenting bacilli that are phenotypically similar but genetically distinct and are 54 
widely distributed in the environment (5). Innate and readily acquired adaptive 55 
resistance with antimicrobial exposure thereby altering expression of certain genes 56 
promote chronic infection and this has been extensively described in literature (3). 57 
This intrinsic resistance to multiple antimicrobials limits the therapeutic options for 58 
Achromobacter spp. infections (5, 6). 59 
The clinical relevance of isolation of Achromobacter spp. in the sputum of CF 60 
patients is unclear. Some studies have proposed a link between decline of lung 61 
function and chronic infection by Achromobacter xylosoxidans especially in patients 62 
with chronic Pseudomonas aeruginosa infections (10). Others on the other hand 63 
postulate that the biofilm-forming ability of Achromobacter xylosoxidans correlates 64 
with poor lung function (11).   65 
A. xylosoxidans is the most frequently isolated species from clinical samples but 66 
there are known difficulties associated with the species identification of 67 




biochemical test, or indeed mass spectrometry, were shown to lack the optimal 69 
discriminatory power needed to characterise Achromobacter isolates at species-level 70 
(1, 13, 14). However, Spilker et al. (15, 16) reported characterization of new 71 
Achromobacter species through sequencing of the nrdA housekeeping gene. 72 
Characterisation of Achromobacter clinical isolates at the species-level and its 73 
relationship with antimicrobial resistance profiles is expected to increase our 74 
understanding of the clinical relevance of colonisation by this seemingly CF-related 75 
bacterium (1).  76 
The aims of this present study were: 77 
i) To identify at species-level all Achromobacter spp. isolates referred to the Scottish 78 
CF antimicrobial susceptibility centre using nrdA sequencing. 79 
ii) To describe species-level antimicrobial susceptibility profiles of Achromobacter 80 
spp. 81 
iii) To determine most promising antimicrobial combination treatment for multidrug-82 
resistant Achromobacter spp. 83 
 84 
2.0 Results  85 
2.1 Study population and geographic metadata 86 
A total of 112 presumptive multidrug-resistant Achromobacter spp. were referred for 87 
extended antimicrobial susceptibility testing. Isolates were collected over an 18 year 88 
period (24 Sep 2001 to 09 Oct 2019) from 9 hospitals: 8 in Scotland and one in 89 




submitted 60/112 samples.  Glasgow and Aberdeen with patient proportions of 91 
17.95% and 12.82% submitted 10 and 17/112 samples respectively. Patient age 92 
ranged from 11 to 78 years with a median age at first referral of 28 years. Study 93 
population comprised of 17 (43.59%) and 22 (56.41%) male and female patients 94 
respectively. Of this population, 18 individuals had single isolate referrals whilst the 95 
remaining 21 individuals had multiple referrals (2-9 isolates per individual) with 96 
colonization periods of 1-10 years (Table 1).  97 
2.2 Species prevalence 98 
nrdA sequencing differentiated the 112 referred isolates into 6 different species. We 99 
observed that A. xylosoxidans (n=88/112, 78.57%) was the most prevalent species 100 
amongst our patients (n=28/39, 71.79%) while A. insuavis was the second most 101 
prevalent Achromobacter spp. (10%). To illustrate the degree of sustained 102 
colonisation at patient level we constructed a neighbour joining tree (Fig 1) which 103 
demonstrates that repeat isolates from patients (>2 submissions) were 104 
representatives of the patients’ first referred isolates for 19 out of the 21 patients 105 
(90.48%). 106 
 2.3 Antimicrobial susceptibility testing 107 
Using 18 antimicrobials susceptibility testing were performed on the 112 108 
Achromobacter isolates. Though unequal sampling was carried out in our study, Fig 109 
2 shows that most of the Achromobacter isolates were resistant (≥ 93.33%) to the 110 
aminoglycosides; amikacin, gentamicin, and tobramycin as well as the 111 




antimicrobials were piperacillin-tazobactam (70.27%), followed by co-trimoxazole 113 
(69.72%) and minocycline (62.39%). Aztreonam had no activity against 114 
Achromobacter spp. (For detailed information, see supplementary data).  Thereafter, 115 
we grouped the first-referred study isolates and determined if differences existed in 116 
the antimicrobial susceptibility patterns (Fig 2). Statistical analysis showed that 117 
susceptibility differences exist for amikacin (p=0.032), gentamicin (p=0.002), 118 
tobramycin (p=0.007), ciprofloxacin (p=0.001), levofloxacin (p<0.001) doxycycline 119 
(p<0.001), minocycline (p=0.005) and ticarcillin/clavulanate (p=0.043). There was no 120 
statistical difference in the susceptibility of both Achromobacter groups to aztreonam, 121 
chloramphenicol, colistin, co-trimoxazole, ceftazidime or piperacillin-tazobactam.  122 
2.4 Antimicrobial synergy testing 123 
Antimicrobial synergy testing was conducted using the direct overlay Etest method 124 
and findings classified using the FICI and SBPI criteria. In summary, a total of 738 125 
antimicrobial combinations were tested with a mean of 6.6 combinations per isolate.   126 
2.4.1 FICI 127 
Using FICI criteria, the rates of synergy and antagonism between pairs of 128 
antimicrobials were 10.57% and 2.30% respectively. Species grouping showed 2-129 
fold higher rate of synergy (11.75%) in A. xylosoxidans (n=604) when compared with 130 
non-xylosoxidans (n=138) cumulatively (5.22 % synergy).  131 
 The rates of antimicrobial antagonism in A. xylosoxidans were 2.32% while in non-132 
xylosoxidans 2.24% was observed. A summary of the most synergistic combinations 133 




tobramycin + ceftazidime (n=23, 34.78% synergy) and tobramycin + imipenem 135 
(n=32, 21.88% synergy). The highest rate of antagonism was observed with 136 
ceftazidime + co-trimoxazole (n=24, 12.50 % antagonism) and minocycline + 137 
ticarcillin-clavulanate (n= 18, 11.11% antagonism). However when grouped as 138 
species; for A. xylosoxidans ceftazidime + imipenem combinations (n=13, 53.85%) 139 
as well as tobramycin with ceftazidime (n=18, 38.89%)/imipenem (n=26, 23.08%) 140 
were the most synergistic combinations. While for non-xylosoxidans the antimicrobial 141 
combination of tobramycin and ceftazidime (n=5/ 20%) was the most synergistic 142 
combination. Interestingly, for A. xylosoxidans (Table 2), cotrimoxazole combinations 143 
followed by tobramycin was the most prevalent synergistic combinations. While in 144 
non-xylosoxidans (Table 3) tobramycin combinations were the most prevalent 145 
synergistic combinations. This suggests that to achieve synergy, antimicrobial 146 
combinations with cotrimoxazole and tobramycin should be explored.  147 
2.4.2 SBPI 148 
But in the laboratory, there is uncertainty about which combinations might be 149 
synergistic in vitro, therefore our laboratory previously proposed use of the SBPI 150 
method. For the 738 antimicrobial combinations tested in all study Achromobacter 151 
spp., the median SBPI was 4.67 while the mean SBPI was 15.20. By species the 152 
median and mean values of 4.00 and 15.79 were observed for A. xylosoxidans while 153 
higher values (10.00 and 23.34) were observed for non- xylosoxidans. 154 
The highest median SBPI for Achromobacter spp. was combinations of levofloxacin 155 
with piperacillin-tazobactam (12.00) or co-trimoxazole (9.63). Tobramycin when 156 




2 demonstrates that highest median SBPI for A. xylosoxidans was combinations of 158 
cotrimoxazole with Ticarcillin-clavulanate (11.33) and imipenem (10.00). Similarly, for 159 
non- xylosoxidans (Table 3) a high SBPI value was obtained for co-trimoxazole 160 
combinations with levofloxacin (31.28) or ceftazidime (SBPI 22.44).  161 
3.0 Discussion  162 
Our study focused on Achromobacter spp. which has been reported as one of the 163 
emerging pathogens found in cystic fibrosis patients (4, 17, 18). As the Scottish CF 164 
antimicrobial reference laboratory we receive only multi and extensively drug 165 
resistant isolates from Scottish hospitals as well as Belfast for antimicrobial synergy 166 
testing.  It is therefore difficult to show that our study is a representative picture of the 167 
Scottish CF population. However, like other studies (3-5, 19) our study reiterates the 168 
dominance of A. xylosoxidans (28 out of 39 patients) amongst the CF population. 169 
Also, with an A. xylosoxidans prevalence of 78.57% our study agrees with the 170 
estimated UK prevalence of 78.4% (3). Amoureux et al. (1) suggested that its 171 
dominant role might be due to either a higher natural abundance or the presence of 172 
favourable selective factors for example the possession of innate resistance to 173 
disinfectants such as quaternary ammonium compounds which ensures its ability to 174 
thrive in clinical samples. Also, A. insuavis was the second most patient carried 175 
Achromobacter spp. but the persistent colonization of A. ruhlandii in our CF 176 
population meant that the latter was the second most isolated species. Previous 177 
studies have demonstrated that persistent CF infections are mainly attributed to A. 178 
xylosoxidans, A. insuavis and A. dolens (5). This was also observed in our study, 179 




is also capable of persisting in the CF airways. The mechanisms of persistence has 181 
not been fully established with several hypotheses postulated. Gade et al. (6) reports 182 
that inter-patient transmission might be possible while Edwards et al. (5) showed that 183 
Achromobacter spp. is patient specific and there was clearance in all but one patient 184 
when treated with oral cotrimoxazole. Also, Dupont et al. (4) reported that the 185 
environmental habitat might not play a role in the reseeding of isolates for patients 186 
with persistent infections. We hypothesize that these isolates may not be entirely 187 
eradicated from the CF airways during treatment and on the development of 188 
favourable conditions multiply and cause pulmonary exacerbations.  This is because 189 
analysis of the antimicrobial susceptibility patterns of isolates from patients with 190 
repeated submissions show similar antimicrobial patterns while results from our nrdA 191 
sequencing demonstrate persistent infection. We also did not observe any evidence 192 
of potential transmission between individuals or shared geographical location. 193 
However, further epidemiological studies on these isolates is necessary to enrich our 194 
knowledge on the mechanisms of persistence.  195 
Coward et al. (3) reported that there are no established guidelines for managing CF 196 
patients who persistently harbour Achromobacter spp. with antimicrobial 197 
susceptibility pattern/testing less defined. Indeed, there is a dearth in the knowledge 198 
of species-level antimicrobial susceptibility patterns as well as the most promising 199 
synergistic combinations. Similar to other studies (3, 19-21) the most active 200 
antimicrobial was piperacillin-tazobactam, and cotrimoxazole at 70% while 201 
minocycline was third at 62%.  As expected, we observed a high resistance of our 202 




to the possession of AxyXY-OprZ efflux system which confer resistance to 204 
aminoglycoside in Achromobacter spp. especially A. xylosoxidans, A. ruhlandii and 205 
A. insuavis which make up 96% of this study. Similarly as observed by Amoureux et 206 
al. (19), Achromobacter spp. was more susceptible to imipenem (47%) compared to 207 
meropenem (37%) although our values (given that our samples were MDR and XDR 208 
strains) had a lower susceptibility percentage. Also, mirrored in our observation as 209 
described in most CF and environmental isolates were high ciprofloxacin (92%) and 210 
aztreonam (100%) resistance while for the newer β-lactam combinations such as 211 
ceftolozane-tazobactam (100%) and ceftazidime-avibactam (78%) our isolates were 212 
resistant to these drugs. This observation was also made by Coward et al. (3). But, 213 
few CF studies have described species antimicrobial susceptibility patterns of 214 
Achromobacter spp. We demonstrate that in Achromobacter spp. differences exist in 215 
the susceptibility of non-xylosoxidans compared with A. xylosoxidans to the 216 
carbapenems, cephalosporins or tetracyclines. The presence of resistance-217 
nodulation-cell-division-type pumps in A. xylosoxidans such as AxyABM, AxyXY-218 
OprZ and TetA confers the cell with the ability to pump cephalosporins, 219 
fluoroquinolones, aztreonam, chloramphenicol, carbapenems and tetracycline out of 220 
the cell (23, 24). Papalia et al. (25) reported that a homologue of AxyABM was 221 
present in A. ruhlandii, therefore conferring it with the ability to expel 222 
chloramphenicol. Further research is needed to determine the presence of efflux 223 
pumps and characterize if present in non-xylosoxidans. 224 
Irrespective of isolate susceptibility, antibiotic exposure gives rise to the emergence 225 




options in patient management. Therefore to reduce toxicity and improve efficacy 227 
while preventing the emergence of drug resistance, multiple antibiotics thought to be 228 
effective as single agents are typically often prescribed in the clinic (26). But there is 229 
limited information on synergistic combination for the treatment of Achromobacter 230 
spp. infections. To the best of our knowledge this is the first time antimicrobial 231 
synergy results are described for Achromobacter spp. to species level. Analysis of 232 
our data showed that there were differences in the synergy observed in both 233 
Achromobacter groups when there was availability of the interpretative guidelines.  234 
For all and first- referred isolates, there was ~50% increase in synergy for A. 235 
xylosoxidans compared to non-xylosoxidans when two CLSI interpretative guidelines 236 
were known. Though not a remit of this study, more research would enhance 237 
knowledge on how the more resistant A. xylosoxidans is able to demonstrate more 238 
synergistic combinations than non-xylosoxidans.  239 
At a genus level, our results demonstrate that for Achromobacter spp. combinations 240 
of ceftazidime + imipenem (50%) was the most synergistic combinations. This is in 241 
contrast with observations made by Saiman et al. (27) which stated that ciprofloxacin 242 
+ meropenem combinations (9%) were the most synergistic combinations. It is worth 243 
noting that not all the combinations were tested at the same frequency and 244 
differences existed in the rates observed for both studies. But, Gómara et al. (26) 245 
reported that due to lack of standardization, differences exist in synergy reported 246 
using different methods. Indeed, Saiman used the checkerboard while our lab used 247 
the direct overlay E-test method. It might also be due to our cut off which analysed 248 




synergy and the non-correlation of synergy and clinical efficacy was the reason our 250 
lab had earlier proposed the use of SBPI (28) as a useful parameter for comparing in 251 
vitro effectiveness of combinations thereby ranking them. Our results suggest that 252 
combinations of cotrimoxazole with several antimicrobials are able to give a high 253 
SBPI values although these values do not predict a synergistic FICI. A major 254 
limitation of our data is the lack of information on the clinical outcomes of our 255 
combinations. Therefore, further investigation is required to assess if there is a 256 
correlation of SPBI values and clinical efficacy.  In clinical practice however, there is 257 
a growing evidence showing the lack of effectiveness seen when guiding 258 
antimicrobial selection based on in vitro synergy testing. Indeed, results from a 259 
randomized, double-blind controlled trial demonstrated that there was no difference 260 
between groups and proposed synergy testing in CF patients should be stopped 261 
(29). However, this study was carried out using multiple-combination bactericidal test 262 
method and with various degrees of agreement in synergy methods, it is possible 263 
that others might be more clinically relevant. Finally, the selected study of multidrug-264 
resistant strains may have overestimated our observation of persistence.  It would be 265 
interesting to how the use of random selection would impact on our results. 266 
In summary, the Achromobacter spp. remains a key emerging pathogen in CF 267 
individuals and has been implicated in pulmonary exacerbations. This research 268 
reiterates the prevalent MDR species that make up the Achromobacter genus and 269 
highlights their susceptibility profiles to several antimicrobials. It also attempts to give 270 
antimicrobial combinations which might be used in the treatment of chronic 271 




patients, accurate identification of Achromobacter spp. will undeniably play a vital 273 
role in approach taken during therapeutic management of CF patients.  274 
 275 
4.0 Materials and method  276 
4.1 Study Isolates 277 
A total of 112 presumptive Achromobacter spp. identified by 8 Scottish and 1 278 
Northern Ireland laboratories were collected over an 18 year period (24th September 279 
2001 – 9th October 2019) when they were sent for extended susceptibility testing. 280 
Isolates were stored in the bacterial preservation system MICROBANKTM (PRO-LAB 281 
DIAGNOSTICS Ontario, Canada) at -80oC. 282 
Isolates were plated on receipt onto Mueller-Hinton agar (MH), MacConkey agar, 283 
Pseudomonas Cetrimide agar and Burkholderia cepacia selective agar plates (All 284 
agar plates manufactured by Oxoid Ltd., Basingstoke, UK). Following 18-24 hr 285 
incubation at 35 oC in ambient air, plates were examined for purity and thereafter 286 
incubated a further 24 hr to confirm for purity. Oxidase testing (Oxoid Ltd., 287 
Basingstoke, UK) was performed as a confirmatory test on 18-24 hr colonies. 288 
Oxidase positive and non-lactose fermenting isolates were accepted as 289 
Achromobacter spp 290 
4.2 nrdA Sequencing  291 
Species identification of isolates was carried out by nrdA sequencing according the 292 
method described by Spilker et al. (15). Briefly, a single colony of Achromobacter 293 




dodecyl sulfate (Sigma-Aldrich, Irvine, UK) and 0.05 N NaOH (Sigma-Aldrich, Irvine, 295 
UK). On heating for 15 mins at 95 oC, 180 µl of high-pressure-liquid-chromatography 296 
grade water (Sigma-Aldrich, Irvine, UK) was added to the suspension. The solution 297 
was centrifuged at 13,300 rpm for 5 mins and the supernatants stored at -20 oC. Full 298 
length nrdA amplification and sequencing was carried out using the nrdA-specific 299 
forward (GAACTGGATTCCCGACCTGTTC) and reverse 300 
(TTCGATTTGACGTACAAGTTCTGG) primers as previously published (15). 301 
Amplified PCR products were sequenced by Eurofins genomics (GATC Biotech AG, 302 
Konstanz, Germany) and sequence chromatograms were visualized and edited 303 
using the SeqMan Pro (DNAStar, Madison, WI, USA). Allele numbers were assigned 304 
to each isolate using the Achromobacter MLST database 305 
(http://pubmlst.org/org/achromobacter/). Trimmed sequences were aligned using 306 
MegAlign Pro (DNAStar, Madison, WI, USA). Clustal W in MegAlign Pro was used to 307 
generate a neighbour joining tree with 1,000 bootstrap replications using default 308 
parameters.  Study isolates were grouped as either A. xylosoxidans or non-309 
xylosoxidans following nrdA identification. 310 
4.3 Minimum Inhibitory Concentration (MIC) testing 311 
MIC testing was performed on MH Agar using the Etest methodology according to 312 
manufacturer’s instructions (Liofilchem, Abruzzi, Italy and BioMerieux, Basingstoke, 313 
UK). The antimicrobials tested were amikacin, gentamicin, tobramycin, ciprofloxacin, 314 
levofloxacin, aztreonam, ceftazidime, piperacillin/tazobactam, imipenem, 315 
meropenem, colistin, chloramphenicol, minocycline and co-trimoxazole. Data relating 316 




included in the analyses up to its stop date (2018). While susceptibility data of 318 
antimicrobials introduced by the service later than 2001, namely doxycycline 319 
(October 2003), Ceftazidime-avibactam (January 2018) and ceftolozane-tazobactam 320 
(January 2018) were included in the analyses from the time of introduction. 321 
In this study, MIC values between the standard doubling dilution scale were rounded 322 
up to the next doubling dilution (e.g. 0.75 = 1.0 mg/L). The MICs for amikacin, 323 
gentamicin, tobramycin, ciprofloxacin, levofloxacin, aztreonam, ceftazidime, 324 
piperacillin/tazobactam, imipenem, meropenem, ticarcillin/clavulanate, doxycycline, 325 
chloramphenicol, minocycline and co-trimoxazole were interpreted as susceptible 326 
(S), intermediate (I) or resistant (R) according to the Clinical and Laboratories 327 
Standards Institute (CLSI) approved interpretive standards for non-328 
enterobacteriaceae (30). Ceftazidime/avibactam, ceftolozane/tazobactam and 329 
colistin were interpreted as per CLSI standards for Pseudomonas aeruginosa (30). In 330 
this study, multidrug-resistance (MDR) was defined as acquired non-susceptibility to 331 
at least one agent in ≥3 antimicrobial groups (31). 332 
4.4 Combination testing 333 
Combination testing was performed using a minimum of six pairs of antimicrobials (A 334 
+ B), as described previously (28). Briefly, MH agar plates were inoculated with two 335 
Etest strips (A and B) placed top to tail according to the manufacturer’s instructions. 336 
After 1 hr to allow antimicrobial migration into the agar, each strip is removed and 337 
fresh Etest is placed in opposite orientation on the imprint (Etest A strip replaced with 338 
fresh Etest B strip and vice versa). Plates were further incubated for 22-24 hrs in 339 




4.4.1 Fractional inhibitory concentration index (FICI) 341 
Indices derived from the combination MIC results were calculated using the MIC 342 
value read off the Etest strip and interpreted as described below. 343 
FICI = (MIC A combination / MIC A single) + (MIC B combination / MIC B single). 344 
Where an MIC was found to be greater than the antimicrobial range tested, the next 345 
doubling dilution above the highest value of the range tested was used to calculate 346 
the FICI (e.g. if an MIC of >256mg/L was found then the FICI was calculated using 347 
512mg/L) (32). The indices were interpreted as: synergy - FICI ≤0.5, no interaction - 348 
FICI >0.5 and ≤4.0 and antagonism - FICI >4.0 (33). 349 
Analyses of species susceptibility to double combinations of antimicrobials tested ≥5 350 
times was carried out when CLSI breakpoints for non-enterobacteriaceae was 351 
known.  352 
4.4.2 Susceptible breakpoint index (SBPI) 353 
SBPI = (Susceptible breakpoint of antimicrobial A / MIC of antimicrobial A combination) + 354 
(Susceptible breakpoint of antimicrobial B / MIC of antimicrobial B combination) (28). The 355 
combination results were graded and reported in rank order of their SBPI results 356 
from highest to lowest SBPI which displays the effectiveness of the combination in 357 
decreasing order. Any combination found to be antagonistic (FICI >4.0), was not 358 
ranked and was not recommended for therapy irrespective of the SBPI result. 359 




Descriptive statistics were derived using Microsoft Office Excel 2013 and IBM SPSS 361 
statistics for windows, Version 24 (IBM Corp., Armonk, N.Y., USA). A two-tailed 362 
Mann Whitney test was performed using GraphPad Prism, Version 8.4.0 (GraphPad 363 
software, San Diego, California, USA). 364 
 365 
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Figure Legends 519 
Table 1. Characteristics of study population and demographics 520 
P00, anonymized participant number; F, female; M, male; -, data unavailable 521 
 522 
Fig 1. Neighbour joining tree illustrating the nrdA clustering of Achromobacter 523 
spp. isolates from patients with repeated submission.  524 
P, patient; 01-38 anonymized number, a-i; repeated samples submitted by patient. 525 
 526 
Fig 2. Achromobacter spp. susceptibility patterns. Percentage susceptibility of 527 
all-referred Achromobacter spp., first-referred isolates (A. xylosoxidans and non-528 
xylosoxidans) to several antimicrobials. AMK, amikacin; GEN, gentamicin; TOB, 529 
tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; ATM, aztreonam; CAZ, ceftazidime; 530 
TZP, piperacillin-tazobactam; IPM, imipenem; MEM, meropenem; COL, colistin; TIM, 531 
ticarcillin-clavulanate; CHL, chloramphenicol; DOX, doxycycline; MIN, minocycline; 532 
SXT, co-trimoxazole 533 
a
 CLSI-approved interpretative standards for non-enterobacteriaceae   534 
b
 CLSI-approved interpretative standards for P. aeruginosa. Colistin resistance may 535 
be over-estimated due to limitations of the diffusion method. 536 
 537 
 538 
Table 2. Summary of antimicrobial combinations tested on A. xylosoxidans 539 
isolates 540 
TOB, tobramycin;  LVX, levofloxacin;  CAZ, ceftazidime; IPM, imipenem; MEM, 541 
meropenem;  TIM, ticarcillin-clavulanate; CHL, chloramphenicol; MIN, minocycline; 542 
SXT, co-trimoxazole 543 
a 
Percentage active when used as a single agent 544 
b 











TOB, tobramycin; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; MIN, 553 
minocycline, SXT, co-trimoxazole; CHL, chloramphenicol 554 
a 
Percentage active when used as a single agent 555 
b 
Number of times the combinations were tested556 
 
 
Participant Sex Location Age at first No of samples Period of 
number submission submitted colonization
(yrs) (yrs)
P01 F Inverclyde 12 5 4
P02 F Glasgow 16 1 -
P03 F Edinburgh 13 6 9
P04 F Edinburgh 20 3 1
P05 M Kilmarnock 11 4 3
P06 M Edinburgh 22 1 -
P07 F Edinburgh 18 8 10
P08 F Dumfries 25 5 5
P09 M Dundee 24 5 8
P10 M Aberdeen 20 7 10
P11 F Aberdeen 16 1 -
P12 M Edinburgh 24 7 8
P13 F Edinburgh 18 6 6
P14 F Edinburgh 54 1 -
P15 F Edinburgh 25 1 -
P16 F Edinburgh 19 9 6
P17 M Edinburgh 23 4 4
P18 M Glasgow 13 4 4
P19 M Edinburgh 28 1 -
P20 F Dundee 33 1 -
P21 M Edinburgh 30 3 3
P22 M Edinburgh 18 2 2
P23 F Aberdeen 21 4 1
P24 M Glasgow 20 1 -
P25 M Aberdeen 48 3 4
P26 F Glasgow 20 1 -
P27 F Aberdeen 30 2 3
P28 F Glasgow 71 1 -
P29 M Edinburgh 32 1 -
P30 F Belfast 69 1 -
P31 F Belfast 44 1 -
P32 F Belfast - 1 -
P33 F Belfast - 1 -
P34 M Glasgow 21 1 -
P35 F Glasgow 24 1 -
P36 F Edinburgh 23 3 2
P37 M Edinburgh 78 2 2
P38 M Edinburgh 16 2 2
P39 M Belfast - 1 -





















P38a A.xylosoxidans_Edinburgh  
P37b A.xylosoxidans_Edinburgh  


















P16i A.ruhlandii_Edinburgh  
P16h A.ruhlandii_Edinburgh  
P16g A.ruhlandii_Edinburgh  
P16f A.ruhlandii_Edinburgh  
P16e A.ruhlandii_Edinburgh  
P16d A.ruhlandii_Edinburgh  
P16c A.ruhlandii_Edinburgh  
P16b A.ruhlandii_Edinburgh  































P27a A.xylosoxidans_Aberdeen  
P21c A.xylosoxidans_Edinburgh  
P21b A.xylosoxidans_Edinburgh  
P21a A.xylosoxidans_Edinburgh  
P18d A.xylosoxidans_Glasgow  
P18c A.xylosoxidans_Glasgow  
P18b A.xylosoxidans_Glasgow  
P18a A.xylosoxidans_Glasgow  
P17d A.xylosoxidans_Edinburgh  
P17c A.xylosoxidans_Edinburgh  
P17b A.xylosoxidans_Edinburgh  
P17a A.xylosoxidans_Edinburgh
0.002




























































































Antimicrobial Synergy Antagonistic SBPI
First ( %Sa )
Second( %Sa 
) Number b % Rank % Rank Median Rank
CAZ (23) IPM (46.6) 13 53.85 1 5.17 5
TOB (0) CAZ (23) 18 38.89 2 3.17 13
TOB (0) IPM (46.6) 26 23.08 3 3.33 10
IPM (46.6) SXT (64.7) 10 20.00 4 10.00 2
CAZ (23) SXT (64.7) 15 20.00 4 13.33 1 8.50 4
MIN (54.1) SXT (64.7) 15 13.33 6 6.67 5 4.67 6
TOB (0) MEM (36.8) 15 13.33 6 2.79 16
TOB (0) TIM (49.3) 15 13.33 6 2.75 18
SXT (64.7) CHL (2.4) 16 12.50 9 9.13 3
TOB (0) SXT (64.7) 10 10.00 10 10.00 3 4.23 8
SXT (64.7) TIM (49.3) 10 10.00 10 11.33 1
LVX (1.1) MIN (54.1) 16 3.33 10
LVX (1.1) TIM (49.3) 10 4.46 7
MIN (54.1) CHL (2.4) 24 3.08 14
MIN (54.1) CAZ (23) 19 3.33 10
MIN (54.1) TIM (49.3) 18 11.11 2 3.08 14
MIN (54.1) IPM (46.6) 11 3.67 9
TOB (0) MIN (54.1) 13 7.69 4 2.79 16






















Antimicrobial Synergy Antagonistic SBPI
First (%Sa) Second (%Sa) Number b % Rank % Rank Median Rank
CAZ (37.5) TOB (4.2) 5 20.00 1 3.42 8
LVX (20.8) MIN (91.7) 6 16.67 2 6.67 3
TOB (4.2) IPM (50) 6 16.67 3 4.33 6
CAZ (37.5) SXT (87.5) 9 4 11.11 1 22.44 2
LVX (20.8) SXT (87.5) 6 5 31.28 1
MIN (91.7) CHL (4.2) 5 7 6.67 3
TOB (4.2) MEM (37.5) 5 4.33 6
CAZ (37.5) MIN (91.7) 5 6.46 5
Table 3. Summary of antimicrobial combinations tested on Non- xylosoxidans isolates
 604 
